Drug maker Dr Reddy’s Laboratories Ltd said Tuesday that it may sell generic copies of popular anti-migraine pill Imitrex in the United States since it has settled a patent dispute with its manufacturer, GlaxoSmithKline Plc.
The generic drug may be launched in the last quarter of 2008, Dr Reddy’s said in a filing to the Bombay Stock Exchange.
Imitrex sales in the United States totaled US$890 million in the year ended in June, the statement said.
The news lifted Dr Reddy’s shares by more than 2 per cent to Rs 722 in trading on the Bombay Stock Exchange.